Top Markets
#1 Pleasing Gold Pleasing Gold +1,510.61%
#2 Ontology Gas Ontology Gas +96.40%
#3 PulseChain PulseChain +61.85%
#4 Osmosis Osmosis +33.22%
#5 BOOK OF MEME BOOK OF MEME +32.36%
#6 Neiro Neiro +30.17%
#7 Collect on Fanable Collect on Fanable +29.35%
#8 Unit Pump Unit Pump +28.42%
#9 Pump.fun Pump.fun +28.42%
#10 Ontology Ontology +25.90%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
Molecure S.A. Molecure S.A.

Molecure S.A.

MOC
Rank in Stocks #26167
Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in... Operating as a biopharmaceutical firm in Poland, Molecure S.A. specializes in the research, development, and commercialization of innovative therapies designed to combat neoplastic (cancer) and inflammatory conditions. The company's pipeline prominently features OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has successfully advanced through Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and sarcoidosis. Additionally, Molecure is progressing its YKL-40 program for cancer and fibrosis, OATD-02 for oncology applications, and a Deubiquitinase program. Established in 2012, this Warsaw-headquartered enterprise adopted the name Molecure S.A. in March 2022, having previously been known as OncoArendi Therapeutics S.A.
Share Price
$1.73
Market Cap
$42.88M
Change (1 day)
2.16%
Change (1 year)
-18.85%
Country
PL
Trade Molecure S.A. (MOC)

Category

Healthcare
Revenue for Molecure S.A. (MOC)
Revenue in Aug 2026 TTM: 0
According to Molecure S.A. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Molecure S.A. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US